AnaCardio Raises €62.5M for Heart-Failure Therapy

AnaCardio has raised enough capital to move its heart-failure programme into a more decisive clinical stage.

What happened

Stockholm-based AnaCardio closed a €62.5 million Series B co-led by Novo Holdings and the Ljungström family office. The financing is intended to fund its oral heart-failure candidate, AC01, through a roughly 400-patient Phase 2b study.

The company is targeting Phase 3 readiness by 2028. Earlier clinical results cited by the company are encouraging, but they remain early-stage findings that still need to be confirmed in a larger, more robust trial.

Why it matters

Heart failure remains a large and difficult market. Many patients continue to experience serious symptoms or poor outcomes despite existing therapies, which leaves room for new treatments that can improve cardiac function or slow disease progression.

AnaCardio’s raise matters because it funds the company through a key clinical inflection point. In biotech, the difference between an interesting mechanism and a valuable company often depends on whether early results survive larger studies. A 400-patient Phase 2b trial should provide a much clearer signal than the earlier dataset.

The bigger picture

Specialist biotech funding is still available for companies with focused programmes, clear clinical milestones and large unmet markets. AnaCardio now has the capital to generate the data that could determine whether AC01 becomes a serious late-stage heart-failure asset or remains an early promise.